The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease

Autor: Heeji Lim, Sang-Won Lee, Jung-Ah Lee, June-Woo Lee, Hyun Ju In, Gyung Tae Chung, Jae Keun Chung, Sun Ju Cho, Young Ki Choi, Jung Sik Yoo
Rok vydání: 2017
Předmět:
0301 basic medicine
Cross Protection
Coxsackievirus
medicine.disease_cause
Antibodies
Viral
03 medical and health sciences
Interferon-gamma
Mice
Immune system
Immunogenicity
Vaccine
stomatognathic system
Neutralization Tests
Formaldehyde
Propiolactone
medicine
Enterovirus 71
Animals
Humans
Neutralizing antibody
Vaccine Potency
Immunity
Cellular
Mice
Inbred BALB C
General Veterinary
General Immunology and Microbiology
biology
business.industry
Immunogenicity
Public Health
Environmental and Occupational Health
Outbreak
Viral Vaccines
biology.organism_classification
Virology
Antibodies
Neutralizing
Survival Analysis
Enterovirus A
Human
030104 developmental biology
Infectious Diseases
Vaccines
Inactivated
Inactivated vaccine
Vaccines
Subunit
biology.protein
Molecular Medicine
Enterovirus
Female
business
Hand
Foot and Mouth Disease
Zdroj: Vaccine. 36(24)
ISSN: 1873-2518
Popis: Coxsackievirus belongs to the Enterovirus genus of the Picornaviridae family and is one of the major pathogens associated with human hand, foot, and mouth disease (HFMD). Historically, outbreaks of HFMD have mainly been caused by enterovirus 71 and coxsackievirus A16. Recently, coxsackieviruses A6 and A10 have been associated with increased occurrences of sporadic HFMD cases and outbreak events globally. In this study, the immunogenicity of coxsackieviruses A6, A10, and A16 (CA6, CA10, and CA16), which were inactivated by formalin or β-propiolactone (BPL) under different conditions, was evaluated as multivalent vaccine candidates. CA6 induced similar immune responses with both inactivation methods, and the immune efficacy of CA10 and CA16 was better following inactivation with BPL than with formalin. There was no sufficient cross-reactivity or cross-protectivity against heterologous strains in groups vaccinated with the BPL-inactivated (BI) monovalent vaccine. Sufficient neutralizing antibody and cell-mediated immune responses were induced in the BI-trivalent vaccinated group. These findings suggest that BI-CA6, CA10, and CA16 are potential multivalent vaccine candidates and that a multivalent vaccine is needed to control HFMD. The coxsackievirus multivalent vaccine could be useful for the development of effective HFMD vaccines.
Databáze: OpenAIRE
Externí odkaz: